VIGL

Vigil Neuroscience, Inc. (VIGL) | Rumor.io

Vigil Neuroscience

VIGL

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about VIGL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

May 29

Vigil Neuroscience, Inc. (VIGL) was acquired on the 22nd, with the company's board showing low activity prior to the deal.
The buyout of VIGL may have occurred before regulatory approval.
VIGL is trading at $7.88, down 0.08% in the early afternoon.

Generated by AI

Sentiment

Of the messages about VIGL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +12.75
Bearish	—	—	—	0% -12.75

Bullish· May 22

$VIGL is set to receive a $10 total buyout price, consisting of $8 in cash and $2 in contingent value rights (CVRs), representing a 333% premium over its previous closing price of $2.31.
The acquisition by Sanofi is part of a larger trend of industry consolidation in the pharmaceutical sector, aimed at shoring up pipelines and addressing shortfalls.
$VIGL's stock price has skyrocketed, reaching a 241% gain, driven by the announcement of the buyout and the potential for future value creation.

Bearish· Jan 23

$VIGL is experiencing high selling pressure in pre-market, which could lead to a significant move.
The stock's low float and high short interest make it a challenging and potentially hazardous investment, with many traders experiencing losses.
$VIGL's price is expected to drop further, with some traders anticipating a move below $3, while others believe it will be a long-term winner despite current short-term losses.

Generated by AI

Topics

Of the messages about VIGL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	77.78%
Controversies	—	—	—	3.97%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	18.25%

Analysts· Feb 1

Morgan Stanley initiated coverage on Vigil Neuroscience with an Equal-Weight rating and a $17 price target.
Jefferies initiated coverage on Vigil Neuroscience with a Buy rating and a $20 price target.
Stifel Nicolaus initiated coverage on Vigil Neuroscience with a Buy rating and a $24 price target.

Announcements· May 27

Vigil Neuroscience (VIGL) downgraded to Hold from Buy at Stifel with a price target of $8, down from $11.
The downgrade follows the proposed all-cash transaction by Sanofi (SNY) for $8 per share.
Individuals representing 16.2% of VIGL's total common shares outstanding have signed voting and support agreements in favor of the deal.

Generated by AI

Community

Of the messages about VIGL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	12.71%
Newcomers	—	—	—	87.29%

May 29

New investors are watching Vigil Neuroscience, Inc.'s stock price, noting its slight decline to $7.88.
Some newcomers are keeping an eye on the company's performance, monitoring its early afternoon trading.
There is interest in the stock's volatility, with a small drop of -0.08% noted in the early afternoon.

Generated by AI

Also Discussed

Investors talking about VIGL also mention

#	Name	Attention
1	PSTX - Poseida Therapeutics, Inc.	——
2	Nkgen Biotech Inc.NKGN	0%0
3	Zentalis Pharmaceuticals, Inc.ZNTL	0%new
4	TRML - Tourmaline Bio, Inc.	——
5	Neurogene Inc.NGNE	0%0
6	ZAPP - Zapp Electric Vehicles Group Limited	——
7	Abivax SAABVX	0.01%-0.01
8	IceCure Medical Ltd.ICCM	0%0
9	Xilio Therapeutics, Inc.XLO	0%0
10	NextPlay Technologies Inc.NXTP	0%0